Taking fish oil supplements (which have EPA and DHA) might help calm down skin inflammation by boosting natural healing chemicals and lowering inflammation signs, but sometimes it works really well and other times it doesn’t — it’s inconsistent.
See the scientific wording
Omega-3 fatty acid supplementation with EPA and DHA is associated with increased production of pro-resolving lipid mediators and decreased levels of inflammatory markers in individuals with inflammatory skin diseases, although the resulting clinical outcomes demonstrate variability across different studies.
Correlational — new studies may shift this
One low-scoring study links this claim to the outcome, but causation is not established.
What the research says
1 study reviewedSupporting (1)
Systematic ReviewReview2025
This study found that taking omega-3 supplements (like fish oil) helps the skin calm down inflammation by making special healing molecules, and many people felt better—but not everyone did, because the studies were small and different. So yes, it supports the claim.
Contradicting (0)
No contradicting studies found yet
That doesn't mean it's settled — it just means no study has tested the opposite.
Quality-weighted scoring: we follow the GRADE framework — each study is rated High, Moderate, Low, or Very Low based on study design, methodology rigor, and risk of bias. A single high-quality RCT can outweigh several weaker observational studies.
Scores reflect study quality, not just count.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting study
How Fit Body Science checks a claim
- 1
We isolate the claim
Health advice from videos, articles and studies is broken down into single, testable claims.
- 2
We find the research
Each claim is matched against peer-reviewed studies, with every source cited by DOI.
- 3
We grade the evidence
Studies are scored on methodology, statistical rigor, transparency and publication quality.
The fitness and health internet is full of confident claims. We check them against real research.
Every claim on this site is traced back to peer-reviewed studies, scored on methodology and reporting quality, and given a verdict you can audit yourself — sources, DOIs and all.
- Full evidence breakdown and mechanism chains
- Ask our AI anything about a claim or its studies
- Get notified when new research changes a verdict
Taking fish oil supplements (which have EPA and DHA) might help calm down skin inflammation by boosting natural healing chemicals and lowering inflammation signs, but sometimes it works really well and other times it doesn’t — it’s inconsistent.
Evidence from Studies
Supporting (1)
Community contributions welcome
Specialized Pro-Resolving Lipid Mediators and Dietary Omega-3/6 Fatty Acids in Selected Inflammatory Skin Diseases: A Systematic Review
This study found that taking omega-3 supplements (like fish oil) helps the skin calm down inflammation by making special healing molecules, and many people felt better—but not everyone did, because the studies were small and different. So yes, it supports the claim.
Contradicting (0)
Community contributions welcome
Score Breakdown
No multi-axis breakdown available yet. The overall Pro / Against score above is the best signal.
- No clinical evidence is available; the score reflects mechanistic plausibility only.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Causal effect of EPA/DHA supplementation on clinical outcomes via biomarker changes
A double-blind, placebo-controlled RCT in 200 adult patients with moderate-to-severe atopic dermatitis, randomized to receive 2.5g EPA + 1.5g DHA daily or placebo for 16 weeks. Primary outcomes: change in EASI score (clinical severity); secondary outcomes: serum levels of resolvin E1 and D1 (pro-resolving mediators), plasma IL-6 and TNF-alpha (inflammatory markers), and skin biopsy analysis of SPMs. All participants maintain standardized skincare routines and avoid other omega-3 sources.
Consistency of association across studies
A systematic review and meta-analysis of all published RCTs and prospective cohort studies (2000–2024) evaluating EPA/DHA supplementation in human inflammatory skin diseases (e.g., psoriasis, atopic dermatitis, rosacea). Inclusion criteria: baseline and post-intervention measurements of at least two pro-resolving lipid mediators (e.g., resolvins, protectins) and two inflammatory markers (e.g., CRP, IL-17, TNF-alpha), plus validated clinical scores. Subgroup analyses by disease type, dosage (>2g vs. ≤2g EPA+DHA), and duration (>12 vs. ≤12 weeks).
Consistency of biomarker response independent of clinical outcomes
A focused meta-analysis of biomarker data from RCTs and pilot studies measuring serum or skin tissue levels of pro-resolving mediators (e.g., RvE1, PD1, MaR1) and inflammatory cytokines (e.g., IL-8, IFN-gamma) pre- and post-EPA/DHA supplementation in inflammatory skin disease patients. Only studies with validated LC-MS/MS or ELISA methods included. Primary outcome: standardized mean difference in mediator levels. Secondary: correlation between biomarker change and clinical improvement.
Naturalistic association over time
A 12-month prospective cohort study of 300 individuals with chronic inflammatory skin disease (e.g., psoriasis) who self-select into EPA/DHA supplement users (≥1.5g/day) or non-users. Serial measurements of serum SPMs, inflammatory cytokines, and SCORAD/EASI scores every 3 months. Covariates: diet, smoking, medications, microbiome. Primary analysis: multivariable regression to assess whether supplement use predicts biomarker and clinical changes over time, adjusting for confounders.
Biological plausibility of mechanism
Primary human keratinocytes and dermal fibroblasts from patients with atopic dermatitis are treated with physiologically relevant concentrations of EPA and DHA (1–10 µM) for 24–72 hours. Outcomes: quantification of resolvin and maresin production via LC-MS/MS, secretion of IL-1β, IL-6, and TNF-alpha via multiplex ELISA, and expression of pro-resolving enzyme genes (ALOX15, 15-LOX) via qPCR. Controls: vehicle and omega-6 fatty acids (e.g., AA).